291 related articles for article (PubMed ID: 29592898)
1. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.
Gowda PS; Wildman BJ; Trotter TN; Xu X; Hao X; Hassan MQ; Yang Y
Mol Cancer Res; 2018 Jul; 16(7):1138-1148. PubMed ID: 29592898
[TBL] [Abstract][Full Text] [Related]
2. Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.
Taipaleenmäki H; Browne G; Akech J; Zustin J; van Wijnen AJ; Stein JL; Hesse E; Stein GS; Lian JB
Cancer Res; 2015 Apr; 75(7):1433-44. PubMed ID: 25634212
[TBL] [Abstract][Full Text] [Related]
3. Myeloma cell-derived Runx2 promotes myeloma progression in bone.
Trotter TN; Li M; Pan Q; Peker D; Rowan PD; Li J; Zhan F; Suva LJ; Javed A; Yang Y
Blood; 2015 Jun; 125(23):3598-608. PubMed ID: 25862559
[TBL] [Abstract][Full Text] [Related]
4. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
[TBL] [Abstract][Full Text] [Related]
5. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
Leone E; Morelli E; Di Martino MT; Amodio N; Foresta U; Gullà A; Rossi M; Neri A; Giordano A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Clin Cancer Res; 2013 Apr; 19(8):2096-106. PubMed ID: 23446999
[TBL] [Abstract][Full Text] [Related]
6. MiR-217 promotes cell proliferation and osteogenic differentiation of BMSCs by targeting DKK1 in steroid-associated osteonecrosis.
Dai Z; Jin Y; Zheng J; Liu K; Zhao J; Zhang S; Wu F; Sun Z
Biomed Pharmacother; 2019 Jan; 109():1112-1119. PubMed ID: 30551361
[TBL] [Abstract][Full Text] [Related]
7. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.
Adamik J; Jin S; Sun Q; Zhang P; Weiss KR; Anderson JL; Silbermann R; Roodman GD; Galson DL
Mol Cancer Res; 2017 Apr; 15(4):405-417. PubMed ID: 28119431
[TBL] [Abstract][Full Text] [Related]
8. MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone.
Huang Q; Jiang Z; Meng T; Yin H; Wang J; Wan W; Cheng M; Yan W; Liu T; Song D; Chen H; Wu Z; Xu W; Li Z; Zhou W; Xiao J
Biochem Biophys Res Commun; 2014 Oct; 453(1):160-5. PubMed ID: 25264196
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.
Tsukamoto S; Løvendorf MB; Park J; Salem KZ; Reagan MR; Manier S; Zavidij O; Rahmat M; Huynh D; Takagi S; Kawano Y; Kokubun K; Thrue CA; Nagano K; Petri A; Roccaro AM; Capelletti M; Baron R; Kauppinen S; Ghobrial IM
Leukemia; 2018 Aug; 32(8):1739-1750. PubMed ID: 29925904
[TBL] [Abstract][Full Text] [Related]
10. Dental Follicle Cells Participate in Tooth Eruption via the RUNX2-MiR-31-SATB2 Loop.
Ge J; Guo S; Fu Y; Zhou P; Zhang P; Du Y; Li M; Cheng J; Jiang H
J Dent Res; 2015 Jul; 94(7):936-44. PubMed ID: 25818585
[TBL] [Abstract][Full Text] [Related]
11. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
[TBL] [Abstract][Full Text] [Related]
12. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway.
Jiang ZY; Jiang JJ; Ma YS; Li HY; Shi W; Fu PL; Xu CF; Lu JZ; Fu D; Xu JG
Biochem Biophys Res Commun; 2018 Nov; 505(4):1003-1009. PubMed ID: 30309658
[TBL] [Abstract][Full Text] [Related]
14. miR-320a regulates cell proliferation and apoptosis in multiple myeloma by targeting pre-B-cell leukemia transcription factor 3.
Lu Y; Wu D; Wang J; Li Y; Chai X; Kang Q
Biochem Biophys Res Commun; 2016 May; 473(4):1315-1320. PubMed ID: 27086852
[TBL] [Abstract][Full Text] [Related]
15. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
Akech J; Wixted JJ; Bedard K; van der Deen M; Hussain S; Guise TA; van Wijnen AJ; Stein JL; Languino LR; Altieri DC; Pratap J; Keller E; Stein GS; Lian JB
Oncogene; 2010 Feb; 29(6):811-21. PubMed ID: 19915614
[TBL] [Abstract][Full Text] [Related]
16. The overexpression of miR-30a affects cell proliferation of chondrosarcoma via targeting Runx2.
Jiang D; Zheng X; Shan W; Shan Y
Tumour Biol; 2016 May; 37(5):5933-40. PubMed ID: 26596830
[TBL] [Abstract][Full Text] [Related]
17. Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Leuk Lymphoma; 2014 Apr; 55(4):911-9. PubMed ID: 23915193
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.
Mrozik KM; Cheong CM; Hewett D; Chow AW; Blaschuk OW; Zannettino AC; Vandyke K
Br J Haematol; 2015 Nov; 171(3):387-99. PubMed ID: 26194766
[TBL] [Abstract][Full Text] [Related]
19. miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1.
Liu Z; Zhang G; Yu W; Gao N; Peng J
Biochem Biophys Res Commun; 2016 Jan; 469(3):692-7. PubMed ID: 26679605
[TBL] [Abstract][Full Text] [Related]
20. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
